It is chasing after Vertex Pharma’s VX-548 ... Surveyor Capital, Medicxi, Logos Capital, Octagon Capital, Piper Heartland Healthcare Capital, and LifeSci Venture Partners, along with existing ...

EST Vertex Pharmaceuticals (VRTX) files automatic mixed securities shelfMaximize Your Portfolio with Data Driven Insights:Leverage the ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Shares of VRTX opened at $453.20 on Tuesday. The company has a quick ratio of 2.20, a current ratio of 2.47 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a 52-week low of $377.85 ...

Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The firm’s fifty day simple moving average is $435.91 and its 200 day simple moving average is $461.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) received an upgrade from Canaccord Genuity after the cystic fibrosis drugmaker exceeded consensus revenue estimates but missed on earnings with its Q4 2024 ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business.

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...